Dysregulated Expression of Dicer and Drosha in Breast Cancer

Min Yan(Zhengzhou University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Hongyan Huang(Aerospace Research Institute of Materials and Processing Technology), Shude Cui(Henan Cancer Hospital), Yi Wan(Jiangnan University), Ting Wang(Jilin University), Zhenzhen Liu(Zhengzhou University)
Pathology & Oncology Research
September 6, 2011
10.1007/s12253-011-9450-3
Cited by 70

Related Papers

Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use
|Nature Genetics|2019|2.2k
A Population-Based Study of Genes Previously Implicated in Breast Cancer
|New England Journal of Medicine|2021|862
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
|Cell Metabolism|2018|420